Inner and outer retinal pathways both contribute to surround inhibition of salamander ganglion cells.
Illumination of the receptive-field surround reduces the sensitivity of a retinal ganglion cell to centre illumination. The steady, antagonistic receptive-field surround of retinal ganglion cells is classically attributed to the signalling of horizontal cells in the outer plexiform layer (OPL). However, amacrine cell signalling in the inner plexiform layer (IPL) also contributes to the steady receptive-field surround of the ganglion cell. We examined the contributions of these two forms of presynaptic lateral inhibition to ganglion cell light sensitivity by measuring the effects of surround illumination on EPSCs evoked by centre illumination. GABA(C) receptor antagonists reduced inhibition attributed to dim surround illumination, suggesting that this inhibition was mediated by signalling to bipolar cell axon terminals. Brighter surround illumination further reduced the light sensitivity of the ganglion cell. The bright surround effects on the EPSCs were insensitive to GABA receptor blockers. Perturbing outer retinal signalling with either carbenoxolone or cobalt blocked the effects of the bright surround illumination, but not the effects of dim surround illumination. We found that the light sensitivities of presynaptic, inhibitory pathways in the IPL and OPL were different. GABA(C) receptor blockers reduced dim surround inhibition, suggesting it was mediated in the IPL. By contrast, carbenoxolone and cobalt reduced bright surround, suggesting it was mediated by horizontal cells in the OPL. Direct amacrine cell input to ganglion cells, mediated by GABA(A) receptors, comprised another surround pathway that was most effectively activated by bright illumination. Our results suggest that surround activation of lateral pathways in the IPL and OPL differently modulate the sensitivity of the ganglion cell to centre illumination.
Ichinose
Tomomi
T
Department of Ophthalmology/Campus Box 8096, Washington University School of Medicine, 660 S. Euclid Avenue, St Louis, MO 63110, USA.
Lukasiewicz
Peter D
PD
D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D002229:Carbenoxolone / Q000494:pharmacology; D003035:Cobalt / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology*; D018756:GABA Antagonists / Q000494:pharmacology; D009433:Neural Inhibition / Q000502:physiology*; D009924:Organ Culture Techniques; D010775:Photic Stimulation; D010852:Picrotoxin / Q000494:pharmacology; D018079:Receptors, GABA / Q000502:physiology; D011963:Receptors, GABA-A / Q000502:physiology; D018080:Receptors, GABA-B / Q000502:physiology; D017661:Receptors, Presynaptic / Q000502:physiology; D012165:Retinal Ganglion Cells / Q000502:physiology*; D014562:Caudata
D001640:Bicuculline; D002229:Carbenoxolone; D003035:Cobalt; D018756:GABA Antagonists; D010852:Picrotoxin; D018079:Receptors, GABA; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D017661:Receptors, Presynaptic; C087200:GABA-C receptor